Novo says NovoRapid approved for the elderly

Thu Sep 20, 4:29 AM ET
Denmark's Novo Nordisk said on Thursday the European Commission had approved its rapid-acting insulin NovoRapid for treatment of diabetes in the elderly and in people with kidney or liver impairment.
The world's biggest maker of insulin said in a statement that NovoRapid had now been established to be safe to use by all people from two years of age with types 1 or 2 diabetes.